2009
DOI: 10.1016/j.suronc.2008.06.006
|View full text |Cite
|
Sign up to set email alerts
|

Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
62
0
3

Year Published

2010
2010
2021
2021

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 67 publications
(68 citation statements)
references
References 207 publications
3
62
0
3
Order By: Relevance
“…When CEA level > 20 ng/mL, the patients at phase Ducks D accounted for 37%. Some early studies also confirmed CEA level was related to distant metastasis of primary tumor, regional lymph nodes and infiltration depth (Lupinacci et al, 2007;Søreide et al, 2009). The initial tumor size at phases A and B was related to CEA level, suggesting that as an independent prognostic index, CEA level is directly proportional to the enlargement of tumor volume (Zorcolo, 2006;Duffy et al, 2007).…”
Section: Discussionmentioning
confidence: 86%
“…When CEA level > 20 ng/mL, the patients at phase Ducks D accounted for 37%. Some early studies also confirmed CEA level was related to distant metastasis of primary tumor, regional lymph nodes and infiltration depth (Lupinacci et al, 2007;Søreide et al, 2009). The initial tumor size at phases A and B was related to CEA level, suggesting that as an independent prognostic index, CEA level is directly proportional to the enlargement of tumor volume (Zorcolo, 2006;Duffy et al, 2007).…”
Section: Discussionmentioning
confidence: 86%
“…[41] Biomarkers such as telomerase and survivin have been used to assess the long term risk of CRC development [42] whilst morphologic biomarkers in patients include neoplastic colorectal polyposis and the presence of aberrant cryptic foci (AFC); the presence of adenomas with Intraepithelial Neoplasm in the colorectal region can also be used in surveillance as surrogate endpoint biomarkers. [43] Paradoxically, most anti-cancer agents do not have wellestablished single predictors of individualized response, however with the advances in 'omics based approaches it should be possible to provide such molecular predictors. For example, MSI has been documented to be an effective predictor of response to fluoropyrimidine therapy, whilst ERCC1 was found to be beneficial in patients using platinum containing anticancer regimen.…”
Section: Patient Evaluation and Therapeutic Loopholesmentioning
confidence: 99%
“…2. Niestabilność genetyczna w CRC; sekwencja "gruczolak-nowotwór złośliwy" rozwija się na tle różnych typów niestabilności genetycznej, w tym epigenetycznego wyciszania genów; wg [39]; za pozwoleniem wydawcy Fig. 2.…”
Section: Fenotyp Metylatora Wysp Cpg (Cimp)unclassified
“…Genetic instability in CRC; the "adenoma-carcinoma" sequence develops on the background of different types of genetic instability, including epigenetic silencing of genes. From [39], with permission from Elsevier Limited, UK ne dopiero w zaawansowanym stadium [23], komórki nowotworowe tracą łączność podczas wzrostu [24], brak limfocytów infiltrujących guz [25], mają gorsze rokowanie [26], ale dobrze odpowiadają na terapię adiuwantową za pomocą 5-fluorouracylu (5-FU) [26]. Dokładne mechanizmy odpowiedzialne za powstanie fenotypu CIMP-H nie są do końca poznane, ale zauważono pewne cechy wspólne pacjentów z tym fenotypem, sugerujące genetyczne podłoże dla CIMP.…”
Section: Fenotyp Metylatora Wysp Cpg (Cimp)unclassified